Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.51 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.51 |
| ▸ | TRPC7 | Q9HCX4 | 1/20 | 0.51 |
| ▸ | SLC9A3 | P48764 | 16/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.38 |
| ▸ | NOS3 | P29474 | 1/20 | 0.34 |
| ▸ | NOS1 | P29475 | 1/20 | 0.34 |
| ▸ | NOS2 | P35228 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2413034 | 1.00 | TRPC6 (0.51) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2409067 | 0.89 | TRPC6 (0.56) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2409989 | 0.89 | TRPC6 (0.56) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL14962380 | 0.89 | TRPC6 (0.61) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2414982 | 0.89 | TRPC6 (0.61) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL12290635 | 0.89 | TRPC6 (0.52) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2409886 | 0.89 | TRPC6 (0.52) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2415549 | 0.86 | TRPC6 (0.50) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2369936 | 0.86 | TRPC6 (0.54) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 | |
| SCHEMBL2413989 | 0.85 | TRPC6 (0.58) | TRPC6TRPC3TRPC7SLC9A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | claimed |
| EP-2542524-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-01-09 | — | — | EP | claimed |
| EP-2368876-A1 | Derivatives of aminoindanes, their preparation and their application in therapeutics | SANOFI (FR) | 2011-09-28 | — | — | EP | claimed |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2542524-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-01-09 | — | — | EP | disclosed |
| EP-2368876-A1 | Derivatives of aminoindanes, their preparation and their application in therapeutics | SANOFI (FR) | 2011-09-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131034-A1 | DERIVATIVES OF AMINOINDANES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | ANXA2, ANXA3, ADM2 | TRPC6 3080/4885TRPC3 2333/4885TRPC7 3887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.